IMUX / Immunic, Inc. - Pemfailan SEC, Laporan Tahunan, Penyata Proksi

As filed with the Securities and Exchange Commission on August 27, 2025

As filed with the Securities and Exchange Commission on August 27, 2025 Registration No.

CALCULATION OF FILING FEE TABLES Immunic, Inc. Table 1: Newly Registered and Carry Forward Securities

Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-8 Immunic, Inc. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Common Stock, par value

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36201 Immunic, I

Presentation, dated August 7, 2025.

Employee Agreement, dated July 9, 2024, between Immunic, Inc. and Jason Tardio

tardioagreementa01 USACTIVE\127388755\V-1 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is dated July 22, 2024 and effective as of July 9, 2024 (the “Effective Date”), by and between IMMUNIC, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 IMMUNIC, INC. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Numbe

Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update – Vidofludimus Calcium Substantially Reduced 24-Week Confirmed Disability Worsening in Phase 2 CALLIPER Trial in Overall Progressive Multiple Sclerosis Study Po

Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update – Vidofludimus Calcium Substantially Reduced 24-Week Confirmed Disability Worsening in Phase 2 CALLIPER Trial in Overall Progressive Multiple Sclerosis Study Population and Across Subtypes, Reinforcing the Drug’s Neuroprotective Potential and Ability to Slow Disease Progression – – Completed Enrollment for Bo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2025 IMMUNIC, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2025 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2025 IMMUNIC, INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2025 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Number

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2025 IMMUNIC, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2025 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Number)

Immunic, Inc. 2019 Omnibus Equity Incentive Plan, as amended

TABLE OF CONTENTS PAGE IMMUNIC, INC. 2019 OMNIBUS EQUITY INCENTIVE PLAN, AS AMENDED ON JUNE 28, 2023, MARCH 4, 2024, AND JUNE 4, 2025 Article 1. Effective Date, Objectives and Duration 1 1.1 Effective Date of the Plan 1 1.2 Objectives of the Plan 1 1.3 Duration of the Plan 1 Article 2. Definitions 1 2.1 “Affiliate” 1 2.2 “Award” 1 2.3 “Award Agreement” 1 2.4 “Board” 2 2.5 “Bonus Shares” 2 2.6 “Cau

Form of Series B Warrant

FORM OF SERIES B WARRANT IMMUNIC, INC. SERIES B WARRANT TO PURCHASE COMMON STOCK OR PRE-FUNDED WARRANTS Warrant Shares: [●] Issue Date: May [●], 2025 IMMUNIC, INC., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [●], or its permitted registered assigns (the “Holder”), is entitled, sub

Underwriting Agreement, dated as of May 28, 2025, by and between Immunic, Inc. and Leerink Partners LLC

IMMUNIC, INC. (a Delaware corporation) Pre-Funded Warrants to Purchase 86,666,667 Shares of Common Stock Series A Warrants to Purchase 86,666,667 Shares of Common Stock Series B Warrants to Purchase 86,666,667 Shares of Common Stock UNDERWRITING AGREEMENT May 28, 2025 Leerink Partners LLC as Representative of the several Underwriters c/o Leerink Partners LLC 1301 Avenue of the Americas, 5th Floor

Form of Pre-Funded Warrant

FORM OF PRE-FUNDED WARRANT PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK IMMUNIC, INC.

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering

Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering NEW YORK, May 29, 2025 /PRNewswire/ — Immunic, Inc. (“Immunic” or the “Company”) (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the pricing of an underwritten public offe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2025 IMMUNIC, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2025 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Number)

Pre-Funded Warrants to Purchase 86,666,667 Shares of Common Stock Series A Warrants to Purchase 86,666,667 Shares of Common Stock (or Pre-Funded Warrants) Series B Warrants to Purchase 86,666,667 Shares of Common Stock (or Pre-Funded Warrants) 260,00

Filed Pursuant to Rule 424(b)(5) Registration No. 333-275717 PROSPECTUS SUPPLEMENT (to Prospectus dated May 31, 2024) Pre-Funded Warrants to Purchase 86,666,667 Shares of Common Stock Series A Warrants to Purchase 86,666,667 Shares of Common Stock (or Pre-Funded Warrants) Series B Warrants to Purchase 86,666,667 Shares of Common Stock (or Pre-Funded Warrants) 260,000,001 Shares of Common Stock und

Form of Series A Warrant

FORM OF SERIES A WARRANT IMMUNIC, INC. SERIES A WARRANT TO PURCHASE COMMON STOCK OR PRE-FUNDED WARRANTS Warrant Shares: [●] Issue Date: May [●], 2025 IMMUNIC, INC., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [●], or its permitted registered assigns (the “Holder”), is entitled, sub

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2025 IMMUNIC, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2025 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Number)

Presentation, dated May 27, 2025

Immunic, Inc. Announces Proposed Public Offering

Immunic, Inc. Announces Proposed Public Offering NEW YORK, May 28, 2025 /PRNewswire/ — Immunic, Inc. (“Immunic” or the “Company”) (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that it has commenced an underwritten public offering of (i) pre-funded warrants to

Pre-Funded Warrants to Purchase Shares of Common Stock Series A Warrants to Purchase Shares of Common Stock (or Pre-Funded Warrants) Series B Warrants to Purchase Shares of Common Stock (or Pre-Funded Warrants) Shares of Common Stock underlying the W

Filed Pursuant to Rule 424(b)(5) Registration No. 333-275717 The information contained in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to the securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36201 Immunic,

Employee Agreement, dated July 9, 2024, between Immunic, Inc. and Jason Tardio

USACTIVE\127388755\V-1 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is dated July 22, 2024 and effective as of July 9, 2024 (the “Effective Date”), by and between IMMUNIC, INC.

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial – Reduced Relative Risk of 24-Week Confirmed Disability Worsening Events by 20% in Overa

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial – Reduced Relative Risk of 24-Week Confirmed Disability Worsening Events by 20% in Overall Study Population Compared to Placebo; Even More Prominent 30% Reduction in High Unmet Need Population of Primary Progressive Multiple Sclerosis – –

Presentation, dated April 30, 2025.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2025 IMMUNIC, INC. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2025 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Numbe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

Form of Placement Agency Agreement

PLACEMENT AGENCY AGREEMENT April 9, 2025 Titan Partners Group LLC, a division of American Capital Partners, LLC 4 World Trade Center, 29th Floor New York, NY 10007 Ladies and Gentlemen: Introductory.

Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments NEW YORK, April 9, 2025 /PRNewswire/ — Immunic, Inc. (“Immunic” or the “Company”) (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the pricing of a registered

5,666,667 Shares of Common Stock Immunic, Inc.

Filed Pursuant to Rule 424(b)(5) Registration No. 333-275717 5,666,667 Shares of Common Stock Immunic, Inc. We are offering 5,666,667 shares of our common stock, par value $0.0001 per share, at a price of $0.90 per share pursuant to this prospectus supplement and the accompanying prospectus. Our common stock is listed on the Nasdaq Global Select Market under the symbol “IMUX”. On April 8, 2025, th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2025 IMMUNIC, INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2025 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Number

Form of Placement Agent Warrant

NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES FOR WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS.

Form of Securities Purchase Agreement

SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 9, 2025, between Immunic, Inc.

Description of Registrant’s Securities

DESCRIPTION OF CAPITAL STOCK General Our authorized capital stock consists of 130,000,000 shares of common stock, par value $0.

List of subsidiaries of the Registrant

Exhibit 21.1 Subsidiaries of the Registrant Set forth below is a list of subsidiaries of the Registrant. All of the subsidiaries listed below are wholly-owned subsidiaries of Immunic, Inc. and are owned directly by Immunic, Inc. Subsidiary Jurisdiction of Formation Immunic AG Germany

Employee Agreement, dated July 9, 2024, between Immunic, Inc. and Jason Tardio

USACTIVE\127388755\V-1 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is dated July 22, 2024 and effective as of July 9, 2024 (the “Effective Date”), by and between IMMUNIC, INC.

Immunic, Inc. Clawback Policy.

IMMUNIC, INC. CLAWBACK POLICY 1.Introduction Immunic, Inc. (the “Company”) believes that it is in the best interests of the Company and its stockholders to create and foster a culture of business ethics, integrity and accountability, and that, among other purposes, reinforces the Company’s incentive compensation philosophy. The Board of Directors (the “Board”) therefore adopts this policy to provi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36201 Immunic, Inc.

Immunic, Inc. Insider Trading Policy.

i IMMUNIC, INC. INSIDER TRADING POLICY AND GUIDELINES WITH RESPECT TO CERTAIN TRANSACTIONS IN SECURITIES Adopted and approved September 29, 2021 ii TABLE OF CONTENTS Page I. INTRODUCTION ............................................................................................................ 1 1) Legal prohibitions on insider trading .............................................................

Presentation, dated February 20, 2025.

Immunic’s Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing – New Data Suggests that IMU-856 Could Be a Potential Oral Treatment Option for Weight Management; Progra

Immunic’s Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing – New Data Suggests that IMU-856 Could Be a Potential Oral Treatment Option for Weight Management; Program Is Phase 2 Ready – – Dose-Dependent Increase of Endogenous GLP-1 Levels Observed in Post Hoc Analysis of Patients From Phase 1b Clinical Trial in Celiac Disease – – Dose-Dependent Reduction of Body Weight Gain and Food Consumption Observed in Preclinical Study – – Webcast to be Held Today, February 20 at 8:00 am ET – NEW YORK, February 20, 2025 – Immunic, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2025 IMMUNIC, INC. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2025 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Nu

JOINT FILING AGREEMENT

EX-99 2 d11606683ex99-a.htm Exhibit A JOINT FILING AGREEMENT The undersigned agree that this Schedule 13G Amendment No. 2 dated February 14, 2025 relating to the Common Stock, par value $0.0001, of Immunic, Inc. shall be filed on behalf of the undersigned. AVIDITY PARTNERS MANAGEMENT LP By Avidity Partners Management (GP) LLC, its general partner By: /s/ Michael Gregory Title: Managing Member AVID

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 IMMUNIC, INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Num

Presentation, dated January 13, 2025.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2024 IMMUNIC, INC. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2024 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Nu

Employment Agreement, dated December 13, 2024, between Immunic, Inc. and Dr. Daniel Vitt.

EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into on December 13, 2024, and effective as of December 16, 2024 (the “Effective Date”), by and between IMMUNIC, INC.

IMUX / Immunic, Inc. / RTW INVESTMENTS, LP Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Immunic, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 4525EP101 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to wh

IMUX / Immunic, Inc. / Avidity Partners Management LP Passive Investment

SC 13G/A 1 d1153043713g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Immunic, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 4525EP101 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des

IMUX / Immunic, Inc. / Adage Capital Management, L.P. - IMMUNIC, INC. Passive Investment

SC 13G 1 p24-3091sc13g.htm IMMUNIC, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Immunic, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 4525EP101 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate bo

JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)

EX-99.1 2 p24-3091ex99.htm JOINT FILING AGREEMENT PURSUANT TO RULE 13D-1(K) EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36201 Immun

Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update – Positive Interim Analysis of Phase 3 ENSURE Program, Unblinded Independent Data Monitoring Committee Confirmed that Predetermined Futility Criteria Have Not Be

Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update – Positive Interim Analysis of Phase 3 ENSURE Program, Unblinded Independent Data Monitoring Committee Confirmed that Predetermined Futility Criteria Have Not Been Met and Recommended Trials Should Continue as Planned – – Ongoing, Twin Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis and Phase 2 CALLIPER

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Num

Employee Agreement, dated July 9, 2024, between Immunic, Inc. and Jason Tardio

tardioemployagmt USACTIVE\127388755\V-1 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is dated July 22, 2024 and effective as of July 9, 2024 (the “Effective Date”), by and between IMMUNIC, INC.

Presentation, dated November 7, 2024.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2024 IMMUNIC, INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2024 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Num

Presentation, dated October 22, 2024.

Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis – Based on a Review of Unblinded Data, an Independent Data Monitoring Committee (IDMC) Confirmed that Predetermin

Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis – Based on a Review of Unblinded Data, an Independent Data Monitoring Committee (IDMC) Confirmed that Predetermined Futility Criteria Have Not Been Met – – IDMC Also Recommended Continuing Trial without Changes, Including no Need for a Potential Upsizing – – ENSURE Program Remains on Track to be Completed in 2026 – – Webcast to be Held Today, October 22, at 8:00 am ET – NEW YORK, October 22, 2024 – Immunic, Inc.

Presentation, dated September 10, 2024.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2024 IMMUNIC, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2024 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File N

Addendum No. 6, dated August 29, 2024, to Employment Agreement, dated April 17, 2020, between Immunic, Inc. and Duane Nash.

ADDENDUM NO. SIX TO EMPLOYMENT AGREEMENT This Addendum Number SIX (this “Addendum”) to the Employment Agreement dated April 17, 2020, as amended as of October 15, 2020, April 15, 2021, March 15, 2022 and December 28, 2022 and October 17, 2023 (the “Employment Agreement”) that was entered into by and between IMMUNIC, INC., a Delaware corporation (the “Company”), and DUANE NASH (the “Executive”), is

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2024 IMMUNIC, INC. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2024 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Numb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 IMMUNIC, INC. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Numbe

Presentation, dated August 8, 2024.

Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update – Jason Tardio, Experienced Multiple Sclerosis Drug Commercialization Executive, Formerly with Novartis and Biogen, Appointed Chief Operating Officer and Presid

Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update – Jason Tardio, Experienced Multiple Sclerosis Drug Commercialization Executive, Formerly with Novartis and Biogen, Appointed Chief Operating Officer and President – – Strengthened Board of Directors with Appointment of Simona Skerjanec, Senior Pharmaceutical Executive and Thought Leader in Brain Health – – O

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36201 Immunic, I

Employee Agreement, dated July 9, 2024, between Immunic, Inc. and Jason Tardio

immunic-jasontardioemplo USACTIVE\127388755\V-1 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is dated July 22, 2024 and effective as of July 9, 2024 (the “Effective Date”), by and between IMMUNIC, INC.

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec – Senior Executive and Thought Leader in Brain Health with Nearly Three Decades of Global Pharmaceutical Experience – – Ser

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec – Senior Executive and Thought Leader in Brain Health with Nearly Three Decades of Global Pharmaceutical Experience – – Served as Neuroimmunology Franchise Head Responsible for Roche’s Blockbuster Launch of Multiple Sclerosis Therapy Ocrevus® – NEW YORK, July 24, 2024 – Im

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2024 IMMUNIC, INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2024 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Number

Immunic Appoints Jason Tardio as Chief Operating Officer and President – Former Novartis and Biogen Executive Brings Extensive Multiple Sclerosis Drug Commercialization Experience to Immunic – – Werner Gladdines, Current Vice President, Program Manag

Immunic Appoints Jason Tardio as Chief Operating Officer and President – Former Novartis and Biogen Executive Brings Extensive Multiple Sclerosis Drug Commercialization Experience to Immunic – – Werner Gladdines, Current Vice President, Program Management & Clinical Development Operations, Promoted to Chief Development Officer – NEW YORK, July 9, 2024 – Immunic, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2024 IMMUNIC, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2024 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Number)

Filing Fee Table.

Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Immunic, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule(1) Amount Registered(2) Proposed Maximum Offering Price per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(3) Equity Common Stock, par value $0.0

Amended and Restated 2021 Employee Stock Purchase Plan, as amended on March 4, 2024.

IMMUNIC, INC. AMENDED AND RESTATED 2021 EMPLOYEE STOCK PURCHASE PLAN TABLE OF CONTENTS Page Article 1. Purpose and Effective Date 1 1.1 Effective Date 1 1.2 Purpose. 1 Article 2. Definitions 1 2.1 “Account” 1 2.2 “Administrator” 1 2.3 “Accumulation Period” 1 2.4 “Base Earnings” 1 2.5 “Board” 1 2.6 “Code” 1 2.7 “Cut-Off Date” 2 2.8 “Effective Date” 2 2.9 “Eligible Employee” 2 2.10 “Employee” 2 2.11

As filed with the Securities and Exchange Commission on July 2, 2024

As filed with the Securities and Exchange Commission on July 2, 2024 Registration No.

2019 Omnibus Equity Incentive Plan, as Amended on June 28, 2023 and March 4, 2024.

TABLE OF CONTENTS PAGE IMMUNIC, INC. 2019 OMNIBUS EQUITY INCENTIVE PLAN, AS AMENDED ON JUNE 28, 2023 and MARCH 4, 2024 Article 1. Effective Date, Objectives and Duration 1 1.1 Effective Date of the Plan 1 1.2 Objectives of the Plan 1 1.3 Duration of the Plan 1 Article 2. Definitions 1 2.1 “Affiliate” 1 2.2 “Award” 1 2.3 “Award Agreement” 1 2.4 “Board” 2 2.5 “Bonus Shares” 2 2.6 “Cause” 2 2.7 “CEO”

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2024 IMMUNIC, INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2024 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Number

$80,000,000 Immunic, Inc. Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-275717 PROSPECTUS SUPPLEMENT (To Prospectus dated May 31, 2024) $80,000,000 Immunic, Inc. Common Stock We previously entered into a sales agreement with Leerink Partners LLC (“Leerink Partners”), dated May 2, 2022 (the “Sales Agreement”), relating to shares of our common stock, par value $0.0001 per share, that we may offer and sell from time t

May 29, 2024

May 29, 2024 VIA EDGAR Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.

Filing Fee Table

Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-3 (Form Type) Immunic, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title (1) Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (1) Maximum Aggregate Offering Price (1) Fee Rate Amount of Registratio

As filed with the Securities and Exchange Commission on May 24, 2024

As filed with the Securities and Exchange Commission on May 24, 2024 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36201 Immunic,

Presentation, dated May 8, 2024.

Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update – Substantially Bolstered Balance Sheet Through a Three-Tranche Private Placement Totaling Up to $240 Million, Extending Cash Runway Into the Third Quarter of 20

Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update – Substantially Bolstered Balance Sheet Through a Three-Tranche Private Placement Totaling Up to $240 Million, Extending Cash Runway Into the Third Quarter of 2025, Based on Initial $80 Million Tranche – – Received Fourth U.S. Patent Directed to Use of Vidofludimus Calcium in Multiple Sclerosis; Multilayered I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 IMMUNIC, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Number)

55,944,850 Shares Immunic, Inc. Common Stock

Filed Pursuant to Rule 424(b)(3) Registration No. 333-277040 55,944,850 Shares Immunic, Inc. Common Stock This prospectus relates solely to the resale or other disposition by the selling stockholders named herein of up to (i) 44,751,286 shares of our common stock and (ii) 11,193,564 shares of our common stock issuable upon exercise of pre-funded warrants, all of which were initially issued by us p

April 26, 2024

April 26, 2024 VIA EDGAR Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.

1200 Avenue of the Americas, Suite 200 New York, New York 10036

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2024 IMMUNIC, INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2024 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Number

Amended and Restated Certificate of Incorporation (incorporated by reference to the Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the SEC on July 17, 2019), as amended by Certificate of Amendment of Amended and Restated Certificate of Incorporation (incorporated by reference to the Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the SEC on March 8, 2024)

CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF IMMUNIC, INC.

As filed with the Securities and Exchange Commission on March 1, 2024 Registration No. 333-277040 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

As filed with the Securities and Exchange Commission on March 1, 2024 Registration No.

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2024 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Nu

Presentation, dated February 22, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36201 Immunic, Inc.

Immunic, Inc. Insider Trading Policy.

i IMMUNIC, INC. INSIDER TRADING POLICY AND GUIDELINES WITH RESPECT TO CERTAIN TRANSACTIONS IN SECURITIES Adopted and approved September 29, 2021 ii TABLE OF CONTENTS Page I. INTRODUCTION ............................................................................................................ 1 1) Legal prohibitions on insider trading .............................................................

List of subsidiaries of the Registrant

Exhibit 21.1 Subsidiaries of the Registrant Set forth below is a list of subsidiaries of the Registrant. All of the subsidiaries listed below are wholly-owned subsidiaries of Immunic, Inc. and are owned directly by Immunic, Inc. Subsidiary Jurisdiction of Formation Immunic AG Germany

Immunic, Inc. Clawback Policy.

IMMUNIC, INC. CLAWBACK POLICY 1.Introduction Immunic, Inc. (the “Company”) believes that it is in the best interests of the Company and its stockholders to create and foster a culture of business ethics, integrity and accountability, and that, among other purposes, reinforces the Company’s incentive compensation philosophy. The Board of Directors (the “Board”) therefore adopts this policy to provi

Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update – Significantly Strengthened Balance Sheet in January 2024 with Execution of Three-Tranche Private Placement of up to $240 Million, Extending Cash Runway Into the Thi

Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update – Significantly Strengthened Balance Sheet in January 2024 with Execution of Three-Tranche Private Placement of up to $240 Million, Extending Cash Runway Into the Third Quarter of 2025 Based on Initial $80 Million Tranche – – Evidence for Neuroprotective Activity of Vidofludimus Calcium from Phase 2 CALLIPER Interi

Description of Registrant’s Securities

DESCRIPTION OF CAPITAL STOCK General Our authorized capital stock consists of 130,000,000 shares of common stock, par value $0.

IMUX / Immunic, Inc. / Deep Track Capital, LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.

IMUX / Immunic, Inc. / RTW INVESTMENTS, LP - IMMUNIC, INC. Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Immunic, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 4525EP101 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to whi

IMUX / Immunic, Inc. / COMMODORE CAPITAL LP Passive Investment

SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Immunic, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 4525EP101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box t

As filed with the Securities and Exchange Commission on February 13, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IMMUNIC, INC. (Ex

As filed with the Securities and Exchange Commission on February 13, 2024 Registration No.

Calculation of Filing Fee tables

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Immunic, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1)(2) Proposed Maximum Offering Price Per Unit(3) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee

1200 Avenue of the Americas, Suite 200 New York, New York 10036

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defini

1200 Avenue of the Americas, Suite 200 New York, New York 10036

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

IMUX / Immunic, Inc. / BIOTECHNOLOGY VALUE FUND L P - SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Immunic, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 4525EP101 (CUSIP Number) January 8,

Joint Filing Agreement

Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated January 18, 2024 with respect to the Common Stock, par value $0.0001 per share of Immunic, Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the pro

IMUX / Immunic, Inc. / Avidity Partners Management LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

IMUX / Immunic, Inc. / Soleus Private Equity Fund III, L.P. - SCHEDULE 13G Passive Investment

SC 13G 1 ea191414-13gsoleus3immunic.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* IMMUNIC, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 4525EP101 (CUSIP Number) January 8, 2024 (Date of Event Which Requires Filing of this Statement) C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2024 IMMUNIC, INC. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2024 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Numb

Presentation, dated January 5, 2024, furnished herewith.

Form of Pre-Funded Warrant

EXHIBIT A NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES.

Securities Purchase Agreement, dated January 4, 2024, by and among the Company and the Investors.

SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of January 4, 2024 (the “Effective Date”) by and among Immunic, Inc.

Immunic, Inc. Announces Private Placement of up to $240 Million

Immunic, Inc. Announces Private Placement of up to $240 Million NEW YORK, January 5, 2024 – Immunic, Inc. (Nasdaq: IMUX) (“Immunic” or the “Company”), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced it has entered into a securities purchase agreement with select accredited inve

Immunic Highlights 2023 Accomplishments and Upcoming Milestones – Evidence for Neuroprotective Activity of Vidofludimus Calcium from Phase 2 CALLIPER Interim Analysis, Consistent Across the Entire Progressive Multiple Sclerosis Population and All Sub

Immunic Highlights 2023 Accomplishments and Upcoming Milestones – Evidence for Neuroprotective Activity of Vidofludimus Calcium from Phase 2 CALLIPER Interim Analysis, Consistent Across the Entire Progressive Multiple Sclerosis Population and All Subtypes – – Phase 3 ENSURE Program in Relapsing Multiple Sclerosis Ongoing – – Improvements in Gut Health Demonstrated in Phase 1b Clinical Trial of IMU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2023 IMMUNIC, INC. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2023 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Nu

Fifth Addendum, dated December 18, 2023, to Service Agreement between Immunic AG and Dr. Andreas Muehler.

DIENSTVERTRAG SERVICE AGREEMENT zwischen between Immunic AG, vertreten durch den Vorsitzenden des Aufsichtsrates Immunic AG, represented by the Chairman of the Supervisory Board - nachfolgend „Gesellschaft" genannt - - hereinafter referred to as the "Company" - und and Herrn Dr.

ifth Addendum, dated December 18, 2023, to Service Agreement between Immunic AG and Dr. Daniel Vitt.

DIENSTVERTRAG SERVICE AGREEMENT zwischen between Immunic AG, vertreten durch den Vorsitzenden des Aufsichtsrates Immunic AG, represented by the Chairman of the Supervisory Board - nachfolgend „Gesellschaft" genannt - - hereinafter referred to as the "Company" - und and Herrn Daniel Vitt, Mr.

Fifth Addendum, dated December 18, 2023, to Service Agreement between Immunic AG and Dr. Hella Kohlhof.

DIENSTVERTRAG SERVICE AGREEMENT zwischen between Immunic AG, vertreten durch den Vorsitzenden des Aufsichtsrates Immunic AG, represented by the Chairman of the Supervisory Board - nachfolgend „Gesellschaft" genannt - - hereinafter referred to as the "Company" - und and Frau Dr.

Employment Agreement, dated December 18, 2023, between Immunic, Inc. and Dr. Andreas Muehler.

EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into on December 18, 2023 and effective as of January 1, 2024 (the “Effective Date”), by and between IMMUNIC, INC.

As filed with the Securities and Exchange Commission on November 22, 2023

As filed with the Securities and Exchange Commission on November 22, 2023 Registration No.

Form of Indenture

Exhibit 4.1 IMMUNIC, INC. Issuer AND as Trustee INDENTURE Dated as of [ ] Debt Securities CROSS-REFERENCE TABLE (1) SECTION OF TRUST INDENTURE ACT OF 1939, AS AMENDED SECTION(S) OF INDENTURE 310(a) 7.9 310(b) 7.8 311(a) 7.13 311(b) 7.13 312(a) 5.1, 5.2(a) 312(b) 5.2(b) 312(c) 5.2(c) 313(a) 5.4 313(b) 5.4 313(c) 5.4 313(d) 5.4 314(a) 5.3, 14.12 314(c) 14.7(a) 314(e) 14.7(b) 315(a) 7.1 315(b) 7.14 3

Filing Fee Table

Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-3 (Form Type) Immunic, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title (1) Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (1) Maximum Aggregate Offering Price (1) Fee Rate Amount of Registratio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 IMMUNIC, INC. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Nu

Immunic, Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Update – Positive Interim Analysis from Phase 2 CALLIPER Trial Showed Improvements in Serum Neurofilament Light Chain for Vidofludimus Calcium, Consistent Throughout th

Immunic, Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Update – Positive Interim Analysis from Phase 2 CALLIPER Trial Showed Improvements in Serum Neurofilament Light Chain for Vidofludimus Calcium, Consistent Throughout the Overall Progressive Multiple Sclerosis Population and All Subtypes – – Notice of Allowance for United States Patent Protecting the Treatment of Rela

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36201 Immun

Presentation, dated November 14, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2023 IMMUNIC, INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2023 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Num

Addendum No. 5, dated October 17, 2023, to Employment Agreement, dated April 17, 2020, between Immunic, Inc. and Duane Nash.

ADDENDUM NO. FIVE TO EMPLOYMENT AGREEMENT This Addendum Number FIVE (this “Addendum”) to the Employment Agreement dated April 17, 2020, as amended as of October 15, 2020, April 15, 2021, March 15, 2022 and December 28, 2022 (the “Employment Agreement”) that was entered into by and between IMMUNIC, INC., a Delaware corporation (the “Company”), and DUANE NASH (the “Executive”), is entered into as of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2023 IMMUNIC, INC. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2023 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Numb

Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis – 24-Week Data from First Half of Patients Shows Improvements in Biomarker NfL, Consistent Throughout the Overall Progressive

Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis – 24-Week Data from First Half of Patients Shows Improvements in Biomarker NfL, Consistent Throughout the Overall Progressive Multiple Sclerosis Population as well as All Subtypes – – NfL Effect in Non-Active Subpopulation Reinforces Vidofludimus Calcium’s Neuroprotective Potential – – Brain Volume Data of the Full 467 CALLIPER Patient Cohort Expected in April 2025 – – Phase 3 ENSURE Program in Relapsing Multiple Sclerosis Ongoing – – Conference Call and Webcast to be Held Tomorrow, October 10, 2023 at 8:00 am ET – NEW YORK, October 9, 2023 – Immunic, Inc.

Presentation, dated October 10, 2023.

Filing Fee Table.

Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) Immunic, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule (3) Amount Registered(1) Proposed Maximum Offering Price per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee (4) Equity Common Stock, par value $0

As filed with the Securities and Exchange Commission on August 21, 2023

As filed with the Securities and Exchange Commission on August 21, 2023 Registration No.

2019 Omnibus Equity Incentive Plan, as Amended

TABLE OF CONTENTS PAGE IMMUNIC, INC. 2019 OMNIBUS EQUITY INCENTIVE PLAN, AS AMENDED Article 1. Effective Date, Objectives and Duration 1 1.1 Effective Date of the Plan 1 1.2 Objectives of the Plan 1 1.3 Duration of the Plan 1 Article 2. Definitions 1 2.1 “Affiliate” 1 2.2 “Award” 1 2.3 “Award Agreement” 1 2.4 “Board” 2 2.5 “Bonus Shares” 2 2.6 “Cause” 2 2.7 “CEO” 2 2.8 “Change in Control” 2 2.9 “C

Immunic, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update – Preclinical Data Published in the Journal of Medicinal Chemistry Identifies Vidofludimus Calcium as a Potent Nurr1 Activator, Reinforcing Neuroprotective Pote

Immunic, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update – Preclinical Data Published in the Journal of Medicinal Chemistry Identifies Vidofludimus Calcium as a Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis – – Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease Provide Proof-of-Concept for a New Therapeu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36201 Immunic, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 IMMUNIC, INC. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Numbe

Presentation, dated August 3, 2023.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2023 IMMUNIC, INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2023 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Number

Immunic, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update – Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease Provide Proof-of-Concept for a New Therapeutic Approach to Treat Gastrointestinal Di

Immunic, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update – Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease Provide Proof-of-Concept for a New Therapeutic Approach to Treat Gastrointestinal Diseases by Promoting Regeneration of Bowel Architecture – – Interim Results From Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple

Presentation, dated May 11, 2023.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36201 Immunic,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 IMMUNIC, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Number)

Presentation, dated May 4, 2023.

Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders – Positive Effects Demonstrated Over Placebo in Four Key Dimens

Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders – Positive Effects Demonstrated Over Placebo in Four Key Dimensions of Celiac Disease Pathophysiology: Protection of Gut Architecture, Improvement of Patients’ Symptoms, Biomarker Response, and Enhancement of Nutrient Absorption – – Corroborates Hypothesized Ability of IMU-856 to Renew Gut Wall and Restore Gut Health – – No Safety or Tolerability Issues Detected – – Conference Call and Webcast to be Held Today, May 4, 2023 at 8:00 am ET – NEW YORK, May 4, 2023 – Immunic, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 IMMUNIC, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Number)

1200 Avenue of the Americas, Suite 200 New York, New York 10036

DEF 14A 1 e618561def14a-immunic.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as pe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2023 IMMUNIC, INC. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2023 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Numbe

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D. – Thought-Leader in Multiple Sclerosis with Decades of Experience in Academic Medicine and the Pharmaceutical Industry –

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D. – Thought-Leader in Multiple Sclerosis with Decades of Experience in Academic Medicine and the Pharmaceutical Industry – NEW YORK, April 27, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2023 IMMUNIC, INC. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2023 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Number

Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis – 50-Week Maintenance Phase Data Shows Dose-Linear Increase in Clinical Remission for Vidofludimus Calciu

Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis – 50-Week Maintenance Phase Data Shows Dose-Linear Increase in Clinical Remission for Vidofludimus Calcium as Compared to Placebo – – 30 mg Once-Daily Dose of Vidofludimus Calcium Demonstrated Statistically Significant Rates of Clinical Remission (p=0.

Presentation, dated April 5, 2023.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 IMMUNIC, INC. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Numbe

IMUX / Immunic Inc / LSP V Cooperatieve U.A. - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to § 240.13d-1(a) and Amendments Thereto Filed Pursuant to § 240.13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 2)* IMMUNIC, INC. (Name of Issuer) Common Stock, Par Value $0.0001 Per Share (Title of Class of Securiti

Service Agreement, dated September 29, 2016, between Immunic AG and Daniel Vitt.

DIENSTVERTRAG SERVICE AGREEMENT zwischen between Immunic AG, vertreten durch den Vorsitzenden des Aufsichtsrates Immunic AG, represented by the Chairman of the Supervisory Board - nachfolgend „Gesellschaft" genannt - - hereinafter referred to as the "Company" - und and Herrn Daniel Vitt, Mr.

Immunic, Inc. Reports Year End 2022 Financial Results and Provides Corporate Update – Initial Results From Ongoing Part C of Phase 1 Clinical Trial of IMU-856 in Celiac Disease Expected Mid-2023 – – Interim Results From Phase 2 CALLIPER Trial of Vido

Immunic, Inc. Reports Year End 2022 Financial Results and Provides Corporate Update – Initial Results From Ongoing Part C of Phase 1 Clinical Trial of IMU-856 in Celiac Disease Expected Mid-2023 – – Interim Results From Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Expected in the Second Half of 2023 – – $116.4 Million in Cash, Cash Equivalents and Investments Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36201 Immunic, Inc.

List of subsidiaries of the Registrant

Exhibit 21.1 Subsidiaries of the Registrant Set forth below is a list of subsidiaries of the Registrant. All of the subsidiaries listed below are wholly-owned subsidiaries of Immunic, Inc. and are owned directly by Immunic, Inc. Subsidiary Jurisdiction of Formation Immunic AG Germany

Description of Registrant's Securities

Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK General Our authorized capital stock consists of 130,000,000 shares of common stock, par value $0.0001 per share, and 20,000,000 shares of preferred stock, par value $0.0001 per share. The following description of our common stock summarizes its material terms and provisions, but it is not complete. For the complete terms of our common stock, please refer t

Service Agreement, dated August 22, 2016, between Immunic AG and Dr. Andreas Muehler.

DIENSTVERTRAG SERVICE AGREEMENT zwischen between Immunic AG, vertreten durch den Vorsitzenden des Aufsichtsrates Immunic AG, represented by the Chairman of the Supervisory Board - nachfolgend „Gesellschaft" genannt - - hereinafter referred to as the "Company" - und and Herrn Dr.

Presentation, dated February 23, 2023

EX-99.2 3 e618296ex99-2.htm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 IMMUNIC, INC. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Nu

IMUX / Immunic Inc / Deep Track Capital, LP Passive Investment

SC 13G/A 1 deeptrack-imux123122a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Immunic, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 4525EP101 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate b

IMUX / Immunic Inc / COMMODORE CAPITAL LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

IMUX / Immunic Inc / RTW INVESTMENTS, LP - IMMUNIC, INC. Passive Investment

SC 13G/A 1 p23-0499sc13ga.htm IMMUNIC, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Immunic, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 4525EP101 (CUSIP Number) December 31, 2022 (Date of event which requires filing of this statement) Check the appropria

IMUX / Immunic Inc / Global Life Bioventure V Sarl - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* IMMUNIC, INC. (Name of Issuer) Common Stock, Par Value $0.0001 per share (Title of Class of Securities) 4525EP 101 (CUSIP Number) 1200 Avenue of the Americas, Suite 200 New York, NY 10036 USA (332) 255-9818 (Name, Address and Telephone Number of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2023 IMMUNIC, INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2023 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Num

Presentation, dated February 9, 2023.

Immunic to Host Virtual Celiac Disease R&D Day to Highlight Current Pathways for Drug Development and Unmet Medical Need

Immunic to Host Virtual Celiac Disease R&D Day to Highlight Current Pathways for Drug Development and Unmet Medical Need – Conference Call and Webcast to be Held Today, February 9, 2023, at 11:00 am ET – NEW YORK, February 9, 2023 – Immunic, Inc.

Fourth Addendum dated January 16, 2023 to the Service Agreement, between Immunic AG and Dr. Andreas Muehler

Vierte Änderungsvereinbarung zum DIENSTVERTRAG vom 22. August 2016 zwischen der Immunic AG, Lochhamer Schlag 21, 82166 Gräfelfing (im Folgenden: „Gesellschaft“) und Herrn Dr. med. Andreas Mühler, Krüner Straße 37, 81373 München (im Folgenden: „Vorstand“) Fourth Addendum to the SERVICE AGREEMENT dated 22 August 2016 between Immunic AG, Lochhamer Schlag 21, 82166 Gräfelfing (hereinafter: “Company”)

Fourth Addendum dated January 16, 2023 to the Service Agreement, between Immunic AG and Dr. Daniel Vitt

Vierte Änderungsvereinbarung zum DIENSTVERTRAG vom 29. September 2016 zwischen der Immunic AG, Lochhamer Schlag 21, 82166 Gräfelfing (im Folgenden: „Gesellschaft“) und Herrn Dr. Daniel Vitt, Obere Bahnhofstr. 7a, 82110 Germering (im Folgenden: „Vorstand“) Fourth Addendum to the SERVICE AGREEMENT dated 29 September 2016 between Immunic AG, Lochhamer Schlag 21, 82166 Gräfelfing (hereinafter: “Compan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2023 IMMUNIC, INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2023 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Num

Fourth Addendum dated January 16, 2023 to the Service Agreement, between Immunic AG and Dr. Hella Kohlhof

Vierte Änderungsvereinbarung zum DIENSTVERTRAG vom 29. September 2016 zwischen der Immunic AG, Lochhamer Schlag 21, 82166 Gräfelfing (im Folgenden: „Gesellschaft“) und Frau Dr. Hella Kohlhof, Stöhrstr. 11, 81477 München (im Folgenden: „Vorstand“) Fourth Addendum to the SERVICE AGREEMENT dated 29 September 2016 between Immunic AG, Lochhamer Schlag 21, 82166 Gräfelfing (hereinafter: “Company”) and D

Addendum No. 4 dated December 28, 2022 to Employment Agreement, between Immunic, Inc. and Duane Nash

ADDENDUM NO. FOUR TO EMPLOYMENT AGREEMENT This Addendum Number Four (this ?Addendum?) to the Employment Agreement dated April 17, 2020, as amended as of October 15, 2020, April 15, 2021 and March 15, 2022 (the ?Employment Agreement?) that was entered into by and between IMMUNIC, INC., a Delaware corporation (the ?Company?), and DUANE NASH (the ?Executive?), is entered into as of December 28, 2022.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2022 IMMUNIC, INC. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2022 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Nu

Common Stock

Common Stock This prospectus relates solely to the resale or other disposition by the selling stockholders named herein of up to (i) 8,696,552 shares of our common stock and (ii) 5,096,552 shares of our common stock issuable upon exercise of pre-funded warrants, all of which were initially issued by us pursuant to the Securities Purchase Agreement dated October 10, 2022 by and among us and the selling stockholders.

December 16, 2022

CORRESP 1 filename1.htm December 16, 2022 VIA EDGAR Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Doris Stacey Gama RE: Immunic, Inc. Registration Statement on Form S-3 File No. 333-268737 Filed December 9, 2022 In accordance with Rule 461 of the Rules and Regulations promulgated under the Securities Act of 1933, as amended,

As filed with the Securities and Exchange Commission on December 9, 2022

As filed with the Securities and Exchange Commission on December 9, 2022 Registration No.

Calculation of Filing Fee tables

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Immunic, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1)(2) Proposed Maximum Offering Price Per Unit(3) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee

IMUX / Immunic Inc / Oetker-von Franquet Suzanne Madeleine - SC 13G Passive Investment

SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Immunic, Inc. (Name of Issuer) Common Stock, $0.0001 Par Value (Title of Class of Securities) 4525EP 101 (CUSIP Number) November 17, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua

IMUX / Immunic Inc / ROI VERWALTUNGS GMBH - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Immunic, Inc. (Name of Issuer) Common Stock, $0.0001 Par Value (Title of Class of Securities) 4525EP 101 (CUSIP Number) November 17, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w

Exhibit 7

Page 5 of 5 Pages Exhibit 7 Pursuant to the instructions in Item 7 of Schedule 13G, the following identifies the subsidiaries which acquired the securities being reported on by Roland Oetker: ROI Verwaltungsgesellschaft mbH

IMUX / Immunic Inc / Oetker Roland - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Immunic, Inc. (Name of Issuer) Common Stock, $0.0001 Par Value (Title of Class of Securities) 4525EP 101 (CUSIP Number) November 17, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2022 IMMUNIC, INC. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2022 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Nu

Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug’s Neuroprotective Potential – Data Show Encouraging Signals for Vidofludimus Calcium for Preventing or Delaying

Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug’s Neuroprotective Potential – Data Show Encouraging Signals for Vidofludimus Calcium for Preventing or Delaying Confirmed Disability Worsening – – Virtual Multiple Sclerosis R&D Day to be Held Today, November 17, 2022 at 11:00 am ET – NEW YORK, November 17, 2022 – Immunic, Inc.

Presentation, dated November 17, 2022

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36201 Immun

Immunic, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update – $72.8 Million in Cash and Cash Equivalents as of September 30, 2022, Plus $56.4 Million of Net Cash Raised in October 2022 Expected to Fund Immunic Into the Fo

Immunic, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update – $72.8 Million in Cash and Cash Equivalents as of September 30, 2022, Plus $56.4 Million of Net Cash Raised in October 2022 Expected to Fund Immunic Into the Fourth Quarter of 2024 – – Webcast to be Held Today, November 3, 2022, at 8:00 am ET – NEW YORK, November 3, 2022 – Immunic, Inc. (Nasdaq: IMUX), a clin

Description of Registrant's Securities

Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK General Our authorized capital stock consists of 130,000,000 shares of common stock, par value $0.0001 per share, and 20,000,000 shares of preferred stock, par value $0.0001 per share. The following description of our common stock summarizes its material terms and provisions, but it is not complete. For the complete terms of our common stock, please refer t

Presentation, dated November 3, 2022.

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Num

JOINT FILING AGREEMENT

Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi

IMUX / Immunic Inc / Point72 Asset Management, L.P. - SCHEDULE 13G Passive Investment

240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. )* (Name of Issuer) Immunic, Inc. (Title of Class of Securities) Common Stock, $0.0001 Par Value Per Share

IMUX / Immunic Inc / COMMODORE CAPITAL LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

IMUX / Immunic Inc / Deep Track Capital, LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

Immunic Reports Pre-Planned Phase 1b Interim Analysis of IMU-935 in Psoriasis Patients Confounded by High Placebo Rate – Interim Analysis Revealed Unexpected High Placebo Rate; Two Active Arms Did Not Separate From Placebo – – No New Safety Signals O

Immunic Reports Pre-Planned Phase 1b Interim Analysis of IMU-935 in Psoriasis Patients Confounded by High Placebo Rate – Interim Analysis Revealed Unexpected High Placebo Rate; Two Active Arms Did Not Separate From Placebo – – No New Safety Signals Observed for IMU-935 in this Trial – – Company Expects to Continue IMU-935 Development in Psoriasis – NEW YORK, October 20, 2022 – Immunic, Inc.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2022 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Num

Immunic, Inc. Announces $60.0 Million Oversubscribed Private Placement Equity Financing

Immunic, Inc. Announces $60.0 Million Oversubscribed Private Placement Equity Financing NEW YORK, October 10, 2022 ? Immunic, Inc. (Nasdaq: IMUX) (?Immunic? or the ?Company?), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced it has entered into a securities purch

Securities Purchase Agreement, dated October 10, 2022, by and among the Company and the Purchasers

Execution Version SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this ?Agreement?) is made and entered into as of October 10, 2022 by and among Immunic, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2022 IMMUNIC, INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2022 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Num

Form of Pre-Funded Warrant

THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR ANY APPLICABLE STATE SECURITIES LAWS AND HAS BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF.

Presentation, dated September 20, 2022.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2022 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File N

Immunic Announces Positive Results from Single and Multiple Ascending Dose Parts of Its Phase 1 Clinical Trial of IMU-856 in Healthy Human Subjects – Unblinded Data Revealed a Favorable Safety, Tolerability and Pharmacokinetic Profile for IMU-856 in

Immunic Announces Positive Results from Single and Multiple Ascending Dose Parts of Its Phase 1 Clinical Trial of IMU-856 in Healthy Human Subjects ? Unblinded Data Revealed a Favorable Safety, Tolerability and Pharmacokinetic Profile for IMU-856 in Single and 14-Day Multiple Dosing ? ? No Maximum Tolerated Dose Reached; Investigated Doses Expected to Exceed Required Therapeutic Dosing of IMU-856 ? ? Third Portion of Phase 1 Clinical Trial in Patients with Celiac Disease Ongoing ? ? Webcast to be Held Today, September 20, 2022, at 8:30 am ET ? NEW YORK, September 20, 2022 ? Immunic, Inc.

Immunic, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update – Initial Clinical Activity Results of IMU-935 in Psoriasis Expected in the Fourth Quarter – – Unblinded Safety Data from the Single and Multiple Ascending Dose

Immunic, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update ? Initial Clinical Activity Results of IMU-935 in Psoriasis Expected in the Fourth Quarter ? ? Unblinded Safety Data from the Single and Multiple Ascending Dose Parts of Phase 1 Clinical Trial of IMU-856 in Healthy Human Subjects Expected in the Third Quarter ? ? $88.1 Million in Cash and Cash Equivalents Exp

Description of Registrant's Securities

Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK General Our authorized capital stock consists of 130,000,000 shares of common stock, par value $0.0001 per share, and 20,000,000 shares of preferred stock, par value $0.0001 per share. The following description of our common stock summarizes its material terms and provisions, but it is not complete. For the complete terms of our common stock, please refer t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36201 Immunic, I

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (C

Presentation, dated August 4, 2022.

Presentation, dated August 4, 2022.

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Numbe

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2022 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Number)

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Maria Törnsén – Global Commercial Executive Brings 20 Years of Sales and Marketing Expertise – – Jan Van den Bossche Steps Down from Board After Six Year Tenure –

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Maria Törnsén – Global Commercial Executive Brings 20 Years of Sales and Marketing Expertise – – Jan Van den Bossche Steps Down from Board After Six Year Tenure – NEW YORK, July 6, 2022 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focus

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2022 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Number

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2022 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Number)

Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update – Trial Did Not Achieve Primary Endpoint in the Ulcerative Colitis (UC) Popu

Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update ? Trial Did Not Achieve Primary Endpoint in the Ulcerative Colitis (UC) Population Caused by Unexpected Interference Between Vidofludimus Calcium and Concurrent Use of Corticosteroids ? ? In UC Population Without Concurrent St

Presentation, dated June 2, 2022.

Description of Registrant's Securities

Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK General Our authorized capital stock consists of 130,000,000 shares of common stock, par value $0.0001 per share, and 20,000,000 shares of preferred stock, par value $0.0001 per share. The following description of our common stock summarizes its material terms and provisions, but it is not complete. For the complete terms of our common stock, please refer t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36201 Immunic,

Immunic, Inc. Reports First Quarter 2022 Financial Results and Provides Corporate Update – Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis Expected Next Month – – Part C Portion of Phase 1 T

Immunic, Inc. Reports First Quarter 2022 Financial Results and Provides Corporate Update ? Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis Expected Next Month ? ? Part C Portion of Phase 1 Trial of IMU-935 in Psoriasis Patients Ongoing; Data Expected in the Second Half of 2022 ? ? Current Cash and Cash Equivalents Expected to Fund Immunic

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2022 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Number)

Presentation, dated May 10, 2022.

Sales Agreement dated as of May 2, 2022, between SVB Securities LLC and Immunic, Inc.

IMMUNIC, INC. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENT May 2, 2022 SVB SECURITIES LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: IMMUNIC, INC., a Delaware corporation (the ?Company?), has previously entered into (i) a Sales Agreement with SVB Securities LLC (the ?Agent?), dated as of July 17, 2019 (the ?2019 Sales Agreement?),

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2022 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Number)

$80,000,000 Immunic, Inc. Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-250083 PROSPECTUS SUPPLEMENT (To Prospectus dated November 24, 2020) $80,000,000 Immunic, Inc. Common Stock We have entered into a sales agreement, or the Sales Agreement, with SVB Securities LLC, dated May 2, 2022, relating to shares of our common stock, par value $0.0001 per share, offered by this prospectus supplement and the accompanying pr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2022 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Numbe

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2022 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Numbe

Addendum No. 3 to Employment Agreement, dated March 15, 2022, between Immunic, Inc. and Duane Nash

ADDENDUM NO. THREE TO EMPLOYMENT AGREEMENT This Addendum Number Three (this ?Addendum?) to the Employment Agreement dated April 17, 2020, as amended as of October 15, 2020 and April 15, 2021 (the ?Employment Agreement?) that was entered into by and between IMMUNIC, INC., a Delaware corporation (the ?Company?), and DUANE NASH (the ?Executive?), is entered into as of March 15, 2022. Defined terms us

IMUX / Immunic Inc / Global Life Bioventure V Sarl - SC 13D/A Activist Investment

SC 13D/A 1 d278732dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* IMMUNIC, INC. (Name of Issuer) Common Stock, Par Value $0.0001 per share (Title of Class of Securities) 4525EP 101 (CUSIP Number) 1200 Avenue of the Americas, Suite 200 New York, NY 10036 USA (332) 255-9818 (Name, A

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Nu

Immunic, Inc. Reports Year End 2021 Financial Results and Highlights Recent Activity – Initiated Enrollment in Phase 3 ENSURE Program of Vidofludimus Calcium for the Treatment of Relapsing Multiple Sclerosis; Final Cohort 2 Data from the Phase 2 EMPh

Immunic, Inc. Reports Year End 2021 Financial Results and Highlights Recent Activity ? Initiated Enrollment in Phase 3 ENSURE Program of Vidofludimus Calcium for the Treatment of Relapsing Multiple Sclerosis; Final Cohort 2 Data from the Phase 2 EMPhASIS Trial Confirms Phase 3 Dose Selection ? ? Completed Enrollment of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerativ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36201 Immunic, Inc.

Presentation, dated February 24, 2022

Description of Registrant's Securities

EX-4.2 2 exhibit42111.htm EX-4.2 Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK General Our authorized capital stock consists of 130,000,000 shares of common stock, par value $0.0001 per share, and 20,000,000 shares of preferred stock, par value $0.0001 per share. The following description of our common stock summarizes its material terms and provisions, but it is not complete. For the complete terms of

List of subsidiaries of the Registrant.

Exhibit 21.1 Subsidiaries of the Registrant Set forth below is a list of subsidiaries of the Registrant. All of the subsidiaries listed below are wholly-owned subsidiaries of Immunic, Inc. and are owned directly by Immunic, Inc. Subsidiary Jurisdiction of Formation Immunic AG Germany

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2022 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Nu

Immunic, Inc. to Present Preclinical Data for Vidofludimus Calcium at the 17th Congress of European Crohn’s and Colitis Organization and Announces Blinded Baseline Characteristics of its Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative C

Immunic, Inc. to Present Preclinical Data for Vidofludimus Calcium at the 17th Congress of European Crohn?s and Colitis Organization and Announces Blinded Baseline Characteristics of its Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis ? Top-Line Data of the CALDOSE-1 Trial Expected to be Available in June of 2022 ? NEW YORK, February 18, 2022 ? Immunic, Inc. (Nasdaq: IMUX), a

IMUX / Immunic Inc / RTW INVESTMENTS, LP - IMMUNIC, INC. Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Immunic, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 4525EP101 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which

Third Addendum, dated January 5, 2022, to Service Agreement between Immunic AG and Dr. Andreas Muehler

Dritte ?nderungsvereinbarung zum DIENSTVERTRAG vom 22. August 2016 Third Addendum to the SERVICE AGREEMENT dated 22nd August 2016 zwischen between der Immunic AG, Lochhamer Schlag 21, 82166 Gr?felfing Immunic AG, Lochhamer Schlag 21, 82166 Gr?felfing (im Folgenden: ?Gesellschaft?) (hereinafter: ?Company?) und and Herrn Dr. med. Andreas M?hler, Kr?ner Stra?e 37, 81373 M?nchen Mr. Dr. med. Andreas M

Presentation, dated January 10, 2022

EX-99.1 5 e621200ex99-1.htm

Third Addendum, dated January 5, 2022, to Service Agreement between Immunic AG and Dr. Hella Kohlhof

Dritte ?nderungsvereinbarung zum DIENSTVERTRAG vom 29. September 2016 Third Addendum to the SERVICE AGREEMENT dated 29th September 2016 zwischen between der Immunic AG, Lochhamer Schlag 21, 82166 Gr?felfing Immunic AG, Lochhamer Schlag 21, 82166 Gr?felfing (im Folgenden: ?Gesellschaft?) (hereinafter: ?Company?) und and Frau Dr. Hella Kohlhof, St?hrstr. 11, 81477 M?nchen Ms. Dr. Hella Kohlhof, St?h

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2022 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Numb

Third Addendum, dated January 5, 2022, to Service Agreement between Immunic AG and Dr. Daniel Vitt

Dritte ?nderungsvereinbarung zum DIENSTVERTRAG vom 29. September 2016 Third Addendum to the SERVICE AGREEMENT dated 29th September 2016 zwischen between der Immunic AG, Lochhamer Schlag 21, 82166 Gr?felfing Immunic AG, Lochhamer Schlag 21, 82166 Gr?felfing (im Folgenden: ?Gesellschaft?) (hereinafter: ?Company?) und and Herrn Daniel Vitt, Obere Bahnhofstr. 7a, 82110 Germering Mr. Daniel Vitt, Obere

Presentation, dated December 14, 2021.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2021 IMMUNIC, INC. (Exact name of registrant as specified in its charter) Delaware 001-36201 56-2358443 (State or other jurisdiction of incorporation) (Commission File Nu